WALTHAM, Mass.--(BUSINESS WIRE)--Regulatory News:
Phase II Combretastatin A4 Phosphate / CA4P study with paclitaxel and carboplatin shows safety, anti-tumor activity, and reduced blood flow
Phase I study of OXi4503 demonstrates safety without reaching dose-limiting toxicity; changes in functional activity observed; study ongoing
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today the publication of two abstracts in the 2007 Annual Meeting program distributed this afternoon at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
